Core Viewpoint - Heng Rui Medicine (01276) has announced the progress of its A-share repurchase plan, indicating a strategic move to enhance shareholder value through share buybacks [1] Group 1: Share Repurchase Details - In November 2025, the company repurchased 979,900 shares through the Shanghai Stock Exchange, accounting for 0.015% of the total share capital, with a maximum purchase price of RMB 63.28 per share and a minimum of RMB 59.32 per share, totaling RMB 59.7885 million (excluding transaction fees) [1] - As of November 30, 2025, the cumulative repurchase amounted to 8,898,700 shares, representing 0.13% of the total share capital, with a maximum price of RMB 70.00 per share and a minimum of RMB 59.32 per share, totaling RMB 595 million (excluding transaction fees) [1]